Table 2 Baseline data of Covid-19 NP swab positive and negative patients
Covid-19 positive patients ( n = 19) | Covid-19 negative patients ( n = 38) | p- value | ||
|---|---|---|---|---|
Age (years) | Mean ± SD | 8.1 ± 4.512 | 6.6 ± 3.41587 | 0.1658 |
Male/female | Ratio | 12/7 | 20/18 | 0.45025 |
Original renal disease: | ||||
FSGS | N (%) | 4 (21) | 8 (21) | 1 |
NPHP | N (%) | 2 (10.67) | 4 (10.5) | 1 |
CIN | N (%) | 2 (10.67) | 6 (15.8) | 0.58 |
VUR | N (%) | 5 (26) | 9 (23.7) | 0.827 |
Bilateral atrophic | N (%) | 4 (21) | 8 (21) | 1 |
kidneys | N (%) | 2 (10.67) | 3 (7.9) | 0.741 |
#Others | ||||
Hypertension | N (%) | 15 (78.9) | 14 (36.8) | 0.0028 |
CKD 5D group | Covid-19 positive patients ( n = 13) | Covid-19 negative patients ( n = 30) | ||
Dialysis duration (months) | Mean ± SD | 14 ± 6.96 | 19.7 ± 9.87 | 0.0664 |
Weight (kg) | Mean ± SD | 17.54 ± 7.74 | 20.12 ± 9.546 | 0.3881 |
Residency (Urban / Rural) | Ratio | 7/6 | 14/16 | 0.6653 |
Dialysis access (CVL / AVF) | Ratio | 6/7 | 21/9 | 0.1337 |
Dialysis adequacy (Kt/v) | Mean ± SD | 1.56 ± 0.45 | 1.61 ± 0.754 | 0.825 |
$Comorbidity | N (%) | 3 (15.8) | 9 (23.7) | 0.642 |
KTR group | Covid-19 positive patients ( n = 6) | Covid-19 negative patients ( n = 8) | ||
Post-TX follow up duration (mo) | Mean ± SD | 9.5 ± 3.69 | 19.4 ± 8.54 | 0.0215 |
Weight (kg) | Mean ± SD | 25.4 ± 11.23 | 31.1 ± 15.1 | 0.4531 |
Baseline serum creatinine (mg/dl) | Mean ± SD | 0.95 ± 0.303 | 0.99 ± 0.45 | 0.7145 |
*Trough level of CNI (ng/dl) | Mean ± SD | 7.58 ± 3.54 | 5.9 ± 3.1 | 0.3631 |
*Daily steroid dose (mg/day) | Mean ± SD | 5 ± 2.25 | 7.5 ± 3.65 | 0.176 |
*Mycofenolate dose (mg/day) | Mean ± SD | 584 ± 210 | 612 ± 325 | 0.8576 |